Revolade, with the active ingredient eltrombopag, is a prescription medication primarily used in the treatment of certain blood disorders related to low platelet counts. Platelets are essential for blood clotting, and low platelet counts can lead to increased bleeding and difficulty in stopping bleeding after an injury. Eltrombopag, the active component in Revolade, belongs to a class of drugs known as thrombopoietin receptor agonists, which work by stimulating the production of platelets in the bone marrow.

Here is a detailed description of Revolade (Eltrombopag) 50 mg Tablets:

1. Mechanism of Action:
   • Eltrombopag works by interacting with the thrombopoietin receptor on cells in the bone marrow, stimulating the production and maturation of platelets.
2. Indications:
   • Revolade is prescribed for the treatment of thrombocytopenia (low platelet count) in adults and children with chronic immune thrombocytopenia (ITP).
   • It may also be used in certain cases of aplastic anemia, where the bone marrow fails to produce an adequate number of blood cells.
3. Dosage:
   • The dosage of Revolade (Eltrombopag) is determined by the healthcare provider based on the individual’s medical condition and response to treatment.
   • It is typically taken orally in the form of tablets.
4. Administration:
   • Revolade tablets are taken once daily, with or without food, as directed by the healthcare provider.
   • It is important for patients to follow the prescribed dosing schedule and instructions.
5. Monitoring:
   • Regular monitoring of platelet counts and other relevant blood parameters is necessary to assess the effectiveness of the treatment and make any necessary dosage adjustments.
6. Potential Side Effects:
   • Common side effects of eltrombopag may include headache, nausea, diarrhea, and an increased risk of blood clots.
   • Serious side effects, though less common, may include liver problems, cataracts, and changes in bone marrow.
7. Precautions:
   • Revolade should be used with caution in individuals with liver problems, and liver function should be monitored regularly during treatment.
   • Patients should inform their healthcare provider of any pre-existing medical conditions or medications they are taking.
8. Interactions:
   • Eltrombopag may interact with certain medications, so it is important for patients to inform their healthcare provider of all medications, supplements, and herbal products they are taking.
9. Pregnancy and Breastfeeding:
   • The use of Revolade during pregnancy and breastfeeding should be discussed with a healthcare provider, as it may pose risks to the unborn child or nursing infant.

Revolade (Eltrombopag) is a valuable treatment option for individuals with chronic immune thrombocytopenia or certain cases of aplastic anemia. However, its use should always be supervised by a qualified healthcare professional who can assess the individual’s specific medical needs, monitor for potential side effects, and make appropriate adjustments to the treatment plan. Patients should follow their healthcare provider’s recommendations closely for optimal safety and efficacy.